Download PDF
Diabetologie und Stoffwechsel 2014; 9(1): 30-33
DOI: 10.1055/s-0033-1362384
Fallbericht
© Georg Thieme Verlag KG Stuttgart · New York

Fallbericht – Nächtliches Ess-Syndrom (NES) bei bipolarer Störung, Depression und Diabetes mellitus Typ 2

Stephan Kress
,
Matthias Kraft
Further Information

Publication History

Publication Date:
31 March 2014 (online)

Also available at
    Permissions and Reprints

Die folgende Kasuistik berichtet über die Wirkung einer GLP1-Therapie auf nächtliche Essattacken bei bipolarer Störung, Depression und Diabetes mellitus Typ 2.

 

  • Literatur

  • 1 McIntyre RS, Rasgon NL, Kemp DE et al. Metabolic syndrome and major depressive disorder: co-occurrence and pathophysiologic overlap. Curr Diab Rep 2009; 9: 51-59
    CrossrefGoogle Scholar
  • 2 McIntyre RS, Danilewitz M, Liauw SS et al. Bipolar disorder and metabolic syndrome: an international perspective. J Affect Disord 2010; 126: 366-387
    CrossrefGoogle Scholar
  • 3 McElroy SL, Kotwal R, Keck Jr PE et al. Comorbidity of bipolar and eating disorders: distinct or related disorders with shared dysregulations?. J Affect Disord 2005; 86: 107-127
    CrossrefGoogle Scholar
  • 4 McElroy SL, Frye MA, Hellemann G et al. Prevalence and correlates of eating disorders in 875 patients with bipolar disorder. J Affect Disord 2011; 128: 191-198
    CrossrefGoogle Scholar
  • 5 Allison KC, Crow SJ, Reeves RR, West DS, Foreyt JP, Dilillo VG, Wadden TA, Jeffery RW, Van Dorsten B, Stunkard AJ. Binge eating disorder and night eating syndrome in adults with type 2 diabetes. Obesity (Silver Spring) 05/2007; 5 (5) 1287-93
    Google Scholar
  • 6 Morse SA, Ciechanowski PS, Katon WJ, Hirsch IB. Isn’t this just bedtime snacking? The potential adverse effects of night-eating symptoms on treatment adherence and outcomes in patients with diabetes. Diabetes Care 2006; 29: 1800-1804
    Google Scholar
  • 7 Allison DB, Montore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ. Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry 1999; 156: 1686-1696
    Google Scholar
  • 8 Elias AN, Hofflich H. Abnormalities in glucose metabolism in patients with schizophrenia treated with atypical antipsychotic medica- tions. American Journal of Medicine 2008; 121: 98-104
    CrossrefGoogle Scholar
  • 9 Kamran A, Doraiswamy PM, Jane JL, Hammett EB, Dunn L. Severe hyperglycemia associated with high doses of clozapine. American Journal of Psychiatry 1994; 151: 1359-1364
    Google Scholar
  • 10 Newcomer JW. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. Journal of Clinical Psychiatry 2004; 65: 36-46
    Google Scholar
  • 11 Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy 2002; 22: 841-852
    CrossrefGoogle Scholar
  • 12 Koller EA, Schneider B, Bennett K. Duditsky, Clozapine-associated diabetes. American Journal of Medicine 2011; 111: 716-723
    Google Scholar
  • 13 Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like Peptide 1 Promotes Satiety and Suppresses Energy Intake in Humans. J Clin Invest 1998; 101: 515-520
    CrossrefGoogle Scholar
  • 14 Holst JJ. Incretin hormones and the satiation signal. lnternational Journal of Obesity 2013; 1-8
    Google Scholar
  • 15 EuroQol Group. EuroQol – a new facility for the measurement of healthrelatedquality of life. Health Policy 1990; 16: 199-208
    CrossrefGoogle Scholar
  • 16 Polonsky WH, Anderson BJ, Lohrer PA, Welch G, Jacobson AM, Aponte JE, Schwartz CE. Assessment of diabetes related distress. Diabetes Care 1995; 18: 754-760
    CrossrefGoogle Scholar
  • 17 McIntyre RS, Alsuwaidan M, Goldstein BI, Taylor VH, Schaffer A, Beaulieu S, Kemp DE. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders. Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force. Ann Clin Psychiatry 2012; 24: 69-81
    Google Scholar
  • 18 Stunkard A, Grace WJ, Wolff HG. The night-eating syndrome; a pattern of food intake among certain obese patients. Am J Med 1955; 19: 78-86
    Google Scholar
  • 19 Lundgren JD, Rempfer MV, Brown CE, Goetz J, Hamera E. The prevalence of night eating syndrome and binge eating disorder among overweight and obese individuals with serious mental illness. Psychiatry Res 2010; 175: 233-236
    CrossrefGoogle Scholar
  • 20 Lundgren JD, Allison KC, Crow S, O’Reardon JP, Berg KC, Galbraith J et al. Pre- valence of the night eating syndrome in a psychiatric population. Am J Psychiatry 2006; 163: 156-158
    Google Scholar
  • 21 Schwandt B, de Zwaan M, Jäger B. Co-morbidity between type 2 diabetes mellitus and night eating. Psychother Psychosom Med Psychol 12/2012; 121 (12) 463-8 DOI: 10. 1055/s-0032–1316348. Epub 2012 Dec 17.
    Article in Thieme ConnectGoogle Scholar
  • 22 Miyaoka T, Yasukawa R, Tsubouchi K, Miura S, Shimizu Y, Sukegawa T, Maeda T, Mizuno S, Kameda A, Uegaki J, Inagaki T, Horiguchi J. Successful treatment of nocturnal eating / drinking syndrome with selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 2003; 18: 175-7
    Google Scholar
  • 23 Ebdrup BH, Knop FK, Ishøy PL, Rostrup E, Fagerlund B, Lublin B, Glenthøj B. Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits. BMC Med 15.08.2012; 10: 92 DOI: 10. 1186/1741-7015-10–92.
    CrossrefGoogle Scholar
  • 24 Gutzwiller JP, Drewe J, Goke B, Schmidt H, Rohrer B, Lareida J et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999; 276 (Pt 2) R1541-R1544
    Google Scholar
  • 25 Kastin AJ, Akerstrom V, Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci 2002; 18: 7-14
    CrossrefGoogle Scholar
  • 26 Göke R, Larsen PJ, Mikkelsen JD, Sheikh SP. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci 1995; 7: 2294-2300
    CrossrefGoogle Scholar
  • 27 mith GS. , Vickers MH. , Cognard E, Shepherd PR. Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: Implications for glucose metabolism and food choice behaviour Schizophrenia Research 2009; 115: 30-34
    Google Scholar
  • 28 Ishøy PL, Knop FK, Vilsbøll T, Glenthøj BY, Ebdrup BH. Sustained weight loss after treatment with a glucagon-like peptide-1 receptor agonist in an obese patient with schizophrenia and type 2 diabetes. Am J Psychiatry 2013; 170: 681-2
    CrossrefGoogle Scholar
  • 29 ClinicalTrials.gov